Awaiting development: Guidance and quality standards

Skip to filters Skip to results

Showing 301 to 325 of 410

Guidance and quality standards awaiting development
Title	Type
Safe prescribing and withdrawal management of prescribed drugs associated with dependence and withdrawal	Quality standard
Safeguarding adults in care homes	Quality standard
Sarizotan for the treatment of respiratory symptoms associated with Rett syndrome [ID1506]	Technology appraisal guidance
Satralizumab for treating thyroid eye disease [ID6648]	Technology appraisal guidance
Savolitinib with osimertinib for treating EGFR-mutated MET-overexpressed or amplified advanced non-small-cell lung cancer after osimertinib [ID6494]	Technology appraisal guidance
Secondary care management of malignant hypertension	Quality standard
Selinexor for maintenance treatment of p53 wild-type advanced or recurrent endometrial cancer after systemic treatment [TSID12374]	Technology appraisal guidance
Selinexor with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma after 1 to 4 treatment lines in people who have not had pomalidomide [ID6705]	Technology appraisal guidance
Selinexor with ruxolitinib for treating splenomegaly or symptoms in myelofibrosis untreated with a JAK inhibitor [ID6717]	Technology appraisal guidance
Semaglutide for managing overweight and obesity in children 6 to 11 years [TSID12381]	Technology appraisal guidance
Semaglutide for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6635]	Technology appraisal guidance
Semaglutide for treating type 2 diabetes [ID1450]	Technology appraisal guidance
Sepiapterin for treating hyperphenylalaninaemia in phenylketonuria in people of any age [ID6750]	Technology appraisal guidance
Serplulimab with carboplatin and nab-paclitaxel for untreated advanced squamous non-small cell lung cancer [GID-TA12040]	Technology appraisal guidance
Serplulimab with chemotherapy for neoadjuvant and adjuvant treatment of untreated gastric cancer [ID6760]	Technology appraisal guidance
Serplulimab with chemotherapy for untreated PD-L1-positive unresectable advanced or recurrent oesophageal squamous cell cancer [GID-TA12038]	Technology appraisal guidance
Serplulimab with pemetrexed and carboplatin for untreated EGFR and ALK mutation-negative advanced non-squamous non-small-cell lung cancer [GID-TA12039]	Technology appraisal guidance
Setrusumab for treating osteogenesis imperfecta [ID6730]	Technology appraisal guidance
Sevabertinib for untreated HER2-positive advanced non-small-cell lung cancer [ID6616]	Technology appraisal guidance
Shared decision-making: practical guidance for health and social care professionals	Quality standard
Sibeprenlimab for treating IgA nephropathy [ID6604]	Technology appraisal guidance
Sigvotatug vedotin for Non-small-cell lung cancer [ID6718]	Technology appraisal guidance
Sleep disordered breathing	Quality standard
Social work interventions for adults with complex needs (including learning disabilities) and mental health needs	Quality standard
Somapacitan for treating growth failure associated with being small for gestational age, Noonan syndrome or idiopathic short height [ID6536]	Technology appraisal guidance

Results per page

10
25
50
All